UnknownPhase 2NCT01279967
A Clinical Trial of ADI-PEG 20TM in Patients With Malignant Pleural Mesothelioma
Studying Pleural mesothelioma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Barts & The London NHS Trust
- Principal Investigator
- Peter SzlosarekBarts and the London NHS
- Intervention
- ADI-PEG 20(drug)
- Enrollment
- 70 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2011 – 2015
Study locations (7)
- The Royal Sussex County Hospital, Brighton, United Kingdom
- Cambridge University Hospitals NHS Foundation Trust, Addenbrooke's Hospital, Cambridge, United Kingdom
- Hull and East Yorkshire Hospitals NHS Trust,The Princess Royal Hospital, Hull, United Kingdom
- Barts and The London NHS, St Bartholomew's Hospital, London, United Kingdom
- Guy's and St Thomas' Foundation Trust, Guy's Hospital, London, United Kingdom
- University Hospital of South Manchester NHS Foundation Trust, Wythenshawe Hospital, Manchester, United Kingdom
- Southampton University Hospitals NHS Trust, Southampton General Hospital, Southampton, United Kingdom
Collaborators
Cancer Research UK · UK: Barts Center for Experimental Cancer Medicine (CECM) for Trial Coordination
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT01279967 on ClinicalTrials.govOther trials for Pleural mesothelioma
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1NCT07532902A Study of BMS-986504 With Standard-of-Care Therapy for People With Solid Tumor CancerMemorial Sloan Kettering Cancer Center
- RECRUITINGPHASE1NCT07443020Fast TILs to Treat Metastatic Pleural Effusions From Epithelial or Mesothelial Primary TumorsAllegheny Singer Research Institute (also known as Allegheny Health Network Research Institute)
- RECRUITINGPHASE1NCT07192900Fast TILs to Treat Metastatic Cancer Patients With Pleural DiseaseDavid Bartlett, MD
- RECRUITINGNANCT07126509Partial Pleurectomy (Surgery) for Unresectable Pleural MesotheliomaUniversity of Chicago
- RECRUITINGPHASE1, PHASE2NCT07121374NEoadjuvant Chemotherapy and Immunotherapy for a Selected Group of Inoperable Pleural Mesothelioma Patients (NECIM): a Feasibility StudyUniversity Hospital, Antwerp
- RECRUITINGPHASE1NCT06885697Anti-Mesothelin TNaive/SCM hYP218 (TNhYP218) CAR T Cells in Participants With Mesothelin-Expressing Solid Tumors Including MesotheliomaNational Cancer Institute (NCI)
- RECRUITINGPHASE2NCT06840834Evaluating Ivonescimab as a Potential Treatment for Pleural Mesothelioma Patients Whose Cancer Has Returned After Previous Immunotherapy and ChemotherapyIntergroupe Francophone de Cancerologie Thoracique
- RECRUITINGPHASE2NCT06875076Multicenter Single-Arm Study of Ivonescimab (AK112) Combined with Chemotherapy in Pretreated Pleural MesotheliomaThe First Hospital of Jilin University